

Title (en)  
FORMULATIONS CONTAINING TRIAZINONES AND IRON

Title (de)  
FORMULIERUNGEN ENTHALTEND TRIAZINONE UND EISEN

Title (fr)  
FORMULATIONS CONTENANT DU TRIAZINONE ET DU FER

Publication  
**EP 3741371 A1 20201125 (DE)**

Application  
**EP 20156985 A 20080521**

Previously filed application  
17160876 20080521 EP

Priority  
• DE 102007025908 A 20070601  
• EP 17160876 A 20080521  
• EP 08758648 A 20080521  
• EP 2008004040 W 20080521

Abstract (en)  
[origin: CA2688613A1] The invention relates to the simultaneous application of triazines such as toltrazuril, ponazuril or diclazuril and iron compounds in a formulation for controlling coccidia infections and iron deficiencies in animals and humans.

Abstract (de)  
Die vorliegende Erfindung betrifft Formulierungen umfassend Triazinone wie insbesondere Toltrazuril und Diclazuril und polynukleare Eisen polysaccharid Komplexverbindungen zusammen mit dem Entschäumer Simethicone zur Bekämpfung von Coccidien-Infektionen und Eisenmangelzuständen insbesondere bei Saugferkeln.

IPC 8 full level  
**A61K 31/53** (2006.01); **A61K 33/26** (2006.01); **A61K 45/06** (2006.01); **A61P 7/06** (2006.01); **A61P 33/02** (2006.01)

CPC (source: EP KR)  
**A61K 9/0095** (2013.01 - EP); **A61K 31/295** (2013.01 - EP); **A61K 31/53** (2013.01 - EP KR); **A61K 31/635** (2013.01 - EP); **A61K 31/7135** (2013.01 - EP); **A61K 33/26** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP); **A61K 47/12** (2013.01 - EP); **A61K 47/36** (2013.01 - EP); **A61P 3/00** (2017.12 - EP); **A61P 3/02** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP)

Citation (search report)  
• [A] EP 0116175 A2 19840822 - BAYER AG [DE]  
• [A] DE 102004042958 A1 20060309 - BAYER HEALTHCARE AG [DE]  
• [A] DE 2413722 A1 19751016 - BAYER AG  
• [A] DE 2718799 A1 19781109 - BAYER AG  
• [Y] BAYER HEALTHCARE-INFORMATION LEAFLET: "Stop coccidiose bij biggen! Baycox 5% oral suspension", 2003, XP002799547, Retrieved from the Internet <URL:https://register.epo.org/application?documentId=E33DQJXH0457DSU&number=EP17160876&lng=en&npl=true>  
• [Y] ANONYMOUS: "Annex I, Summary of product characteristics - Baycox Multi 50 mg/ml oral suspension for Cattle,Pigs and Sheep (version 8)", 1 January 2007 (2007-01-01), XP002799548, Retrieved from the Internet <URL:https://register.epo.org/application?documentId=E1ZCPW881170DSU&number=EP08758648&lng=en&npl=true>  
• [T] RAYMOND C ROWE: "Handbook of Pharmaceutical Excipients - Sixth Edition", 2008, PHARMACEUTICAL PRESS, ISBN: 978-0-85369-792-3, pages: Frontpg., I, 619 - 620, XP002799549  
• [A] KOLB E ET AL: "Significance, metabolism and administration of iron compounds to pigs: A review", TIERAERZTLICHE UMSCHAU, vol. 60, no. 7, July 2005 (2005-07-01), pages 365 - 371, XP008107513, ISSN: 0049-3864  
• [A] ABD-ELZAHER MOKHLES M ET AL: "Biological studies of newly synthesized ferrocenyl complexes containing triazinone moiety", APPLIED ORGANOMETALLIC CHEMISTRY, vol. 20, no. 10, October 2006 (2006-10-01), pages 597 - 602, XP002533027, ISSN: 0268-2605

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**DE 102007025908 A1 20081204**; AR 066780 A1 20090909; BR 122019020753 B1 20200609; BR 122019020753 B8 20210727; BR PI0812172 A2 20141202; BR PI0812172 B1 20200303; BR PI0812172 B8 20210525; CA 2688613 A1 20081204; CA 2688613 C 20170221; CL 2008001533 A1 20081205; CN 101678031 A 20100324; CN 101678031 B 20130612; CO 6241102 A2 20110120; CR 11121 A 20100406; DK 3210610 T3 20200518; EP 2164496 A2 20100324; EP 2164496 B1 20170412; EP 3210610 A1 20170830; EP 3210610 B1 20200422; EP 3692993 A1 20200812; EP 3711766 A1 20200923; EP 3741371 A1 20201125; ES 2624794 T3 20170717; ES 2789775 T3 20201026; FR 20C1049 I1 20201127; HK 1141993 A1 20101126; HR P20170719 T1 20170728; HR P20200777 T1 20200724; HU E031907 T2 20170828; HU E049978 T2 20201130; HU S1900046 I1 20191128; HU S2000041 I1 20201130; JP 2010528996 A 20100826; JP 5591692 B2 20140917; KR 101517861 B1 20150518; KR 20110022510 A 20110307; LT 3210610 T 20200525; MX 2009012406 A 20091209; MX 336910 B 20160202; MX 351332 B 20171011; NI 200900206 A 20110810; PE 20090757 A1 20090723; PL 2164496 T3 20170831; PL 2164496 T4 20191231; PL 3210610 T3 20200727; PT 2164496 T 20170522; PT 3210610 T 20200518; RU 2009148585 A 20110720; RU 2506081 C2 20140210; RU 2506081 C9 20140927; SI 2164496 T1 20170630; SI 3210610 T1 20200731; TW 200914025 A 20090401; TW I417101 B 20131201; UA 97985 C2 20120410; UY 31106 A1 20090105; WO 2008145281 A2 20081204; WO 2008145281 A3 20090813; WO 2008145281 A8 20091126

DOCDB simple family (application)  
**DE 102007025908 A 20070601**; AR P080102283 A 20080530; BR 122019020753 A 20080521; BR PI0812172 A 20080521; CA 2688613 A 20080521; CL 2008001533 A 20080527; CN 200880018446 A 20080521; CO 09132235 A 20091120; CR 11121 A 20091119; DK 17160876 T 20080521; EP 08758648 A 20080521; EP 17160876 A 20080521; EP 2008004040 W 20080521; EP 20156974 A 20080521; EP 20156985 A 20080521; EP 20166703 A 20080521; ES 08758648 T 20080521; ES 17160876 T 20080521; FR 20C1049 C 20201014; HK 10108440 A 20100906; HR P20170719 T 20170512; HR P20200777 T 20200513; HU E08758648 A 20080521; HU E17160876 A 20080521; HU S1900046 C 20191010; HU S2000041 C 20201012; JP 2010509712 A 20080521; KR 20097026881 A 20080521; LT 17160876 T 20080521; MX 2009012406 A 20080521; MX 2015014084 A 20080521; NI 200900206 A 20091117; PE 2008000901 A 20080527; PL 08758648 T 20080521;

PL 17160876 T 20080521; PT 08758648 T 20080521; PT 17160876 T 20080521; RU 2009148585 A 20080521; SI 200831800 A 20080521;  
SI 200832120 T 20080521; TW 97119984 A 20080530; UA A200913980 A 20080521; UY 31106 A 20080527